<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923114</url>
  </required_header>
  <id_info>
    <org_study_id>NL67316.091.18</org_study_id>
    <nct_id>NCT03923114</nct_id>
  </id_info>
  <brief_title>Imaging Pituitary ActiVation by Exendin</brief_title>
  <acronym>iPAVE</acronym>
  <official_title>iPAVE - Imaging Pituitary ActiVation by Exendin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal is the comparison of pituitary uptake of Ga-68-NODAGA-exendin-4 in patients
      with and without adequate response (based on HbA1c or weight loss) to GLP-1R agonist
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of type 2 diabetes (T2D) is increasing and a better understanding of the
      mechanisms of T2D becomes increasingly important. The glucagon-like peptide 1 receptor
      agonists (GLP-1RA), such as exendin, can be used as potent antidiabetic drugs for treatment
      of T2D. Not all patients with T2D respond to treatment with GLP-1RA and some even respond
      with contradictory effects, but the underlying mechanism for this observation remains
      unclear. Interestingly, uptake of an exendin-based radiotracer was observed in the pituitary
      gland in diabetes patients. In this study, the effect of GLP-1RA on the HPA axis will be
      further studied for an improved understanding of the mechanisms and contradictory treatment
      responses.

      Patient data will be obtained and will consist of metabolic characterization (laboratory
      parameters and oral glucose tolerance test), an ACTH assay and determination of cortisol
      excretion. In addition, Ga-68-NODAGA-exendin-4 PET/CT imaging will be performed in 10
      patients with treatment response (decrease in HbA1c or weight loss) and 10 patients without
      response after GLP-1RA therapy. In 5 patients with high radiotracer uptake, an additional
      brain MRI scan will be performed for improved anatomical referencing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pituitary uptake of Ga-68-NODAGA-exendin</measure>
    <time_frame>1.5 year</time_frame>
    <description>Comparison of the pituitary uptake (Bq) of Ga-68-NODAGA-exendin-4 obtained by quantitative analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic status (OGTT)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Assessment of the metabolic status by performing an OGTT (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic status (ACTH)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Assessment of the metabolic status by performing an ACTH assay (mol/l)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patient group with treatment response</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PET/CT imaging of patients with response to GLP-1 receptor agonist treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient group without treatment response</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ga-68-NODAGA-exendin-4 PET/CT</intervention_name>
    <description>PET/CT imaging after injection with Ga-68-NODAGA-exendin-4</description>
    <arm_group_label>Patient group with treatment response</arm_group_label>
    <arm_group_label>Patient group without treatment response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with treatment response:

          -  Age ≥18 years

          -  Subject is diagnosed with type 2 diabetes

          -  Subject showed response to GLP-1RA treatment

          -  Ability to sign informed consent

        Patients without treatment response:

          -  Age ≥18 years

          -  Subject is diagnosed with type 2 diabetes

          -  Subject showed no response to GLP-1RA treatment

          -  Ability to sign informed consent

        Exclusion Criteria:

          -  Liver disease

          -  Renal disease

          -  Pregnancy or the wish to become pregnant within 6 months after the study

          -  Breastfeeding

          -  Age &lt;18 years

          -  Pituitary disorder

          -  Inability to sign informed consent

          -  Exclusion criteria for MR:

               -  Fragments, clips or devices in brain, eyes, spinal canal

               -  Implantable defibrillator or pacemaker (wires)

               -  Mandibular magnetic implants

               -  Neurostimulator, bladder stimulator, non-removable insulin pump

               -  Metal tissue-expander in chest

               -  Cochlear implant

               -  Ossicular replacement prosthesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tom Jansen, MSc</last_name>
    <phone>0031243667244</phone>
    <email>tom.jp.jansen@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marti Boss, MSc</last_name>
    <phone>0031243613813</phone>
    <email>marti.boss@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Jansen, MSc</last_name>
      <phone>0031243667244</phone>
      <email>tom.jp.jansen@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marti Boss, MSc</last_name>
      <phone>0031243613813</phone>
      <email>marti.boss@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exendin</keyword>
  <keyword>GLP-1 receptor agonist</keyword>
  <keyword>HPA-axis</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

